Highlights
- Biocon’s U.S. subsidiary received supplemental U.S. FDA approval for Yesintek® single-dose prefilled autoinjector formats.
- The approved formats include Yesintek® 45 mg/0.5 ml and Yesintek® 90 mg/ml single-dose prefilled autoinjectors.
- Yesintek® was originally approved by the U.S. FDA on November 29, 2024.
- The product is indicated for multiple autoimmune conditions, including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
- The approval expands Biocon’s immunology product portfolio in the United States.
Biocon Receives Additional U.S. FDA Approval for Yesintek
Biocon Limited announced that its subsidiary in the United States has received supplemental approval from the U.S. Food and Drug Administration (FDA) for additional delivery formats of Yesintek® (ustekinumab-kfce).
The approval covers Yesintek® 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek® 90 mg/ml single-dose prefilled autoinjector formats.
Yesintek® was originally approved by the U.S. FDA on November 29, 2024. The latest approval expands the available delivery options for the medicine.
New Delivery Format Expands Treatment Options
The newly approved single-dose prefilled autoinjector format provides patients with an additional treatment option.
Biocon stated that the new delivery format supports more tailored treatment approaches across different care settings and patient requirements.
The approval adds another administration option within Biocon’s immunology portfolio in the United States.
Yesintek Indications Across Autoimmune Conditions
Yesintek® is indicated for the treatment of multiple autoimmune conditions.
The approved uses include moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients aged 6 years and above.
The product is also indicated for moderate to severely active Crohn’s disease and ulcerative colitis in adults.
These conditions involve immune-system-related inflammation and require long-term treatment approaches.
Expanding Biocon’s Immunology Portfolio
The supplemental FDA approval further expands Biocon’s immunology product portfolio in the United States.
The company stated that the development supports its focus on improving access to affordable medicines for patients globally.
The latest approval builds on the existing U.S. FDA approval of Yesintek received in November 2024 by adding new prefilled autoinjector delivery formats.
Regulatory Approval Strengthens Product Availability
Regulatory approvals play an important role in expanding treatment availability by allowing companies to introduce additional product formats for approved medicines.
In the case of Yesintek®, the latest approval relates specifically to the single-dose prefilled autoinjector formats, while the product’s therapeutic indications remain focused on autoimmune conditions outlined in the company statement.
Impact on Biocon’s Healthcare Portfolio
For Biocon, the Yesintek approval represents an additional development within its biologics and immunology portfolio.
The company’s statement did not disclose revenue expectations, pricing details, commercial launch timelines, patient numbers or financial impact associated with the approval.
The announcement is therefore primarily a regulatory update related to product availability and portfolio expansion.
Conclusion
Biocon’s U.S. subsidiary has received supplemental U.S. FDA approval for Yesintek® single-dose prefilled autoinjector formats, including 45 mg/0.5 ml and 90 mg/ml versions. The product was originally approved by the U.S. FDA in November 2024 and is indicated for several autoimmune conditions, including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The latest approval expands the available delivery formats for Yesintek® and adds to Biocon’s immunology portfolio in the United States.
FAQs
Q: What approval did Biocon receive for Yesintek?
A: Biocon’s U.S. subsidiary received supplemental U.S. FDA approval for Yesintek® single-dose prefilled autoinjector formats.
Q: Which Yesintek formats received approval?
A: The approved formats are Yesintek® 45 mg/0.5 ml and Yesintek® 90 mg/ml single-dose prefilled autoinjectors.
Q: When was Yesintek originally approved by the U.S. FDA?
A: Yesintek® was originally approved by the U.S. FDA on November 29, 2024.
Q: What conditions is Yesintek indicated for?
A: Yesintek® is indicated for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Q: Did Biocon disclose any financial impact from the approval?
A: No. The company statement did not disclose any revenue, earnings or financial impact related to the approval.